HK Stock Market Move | KEYMED BIO-B(02162) rises by over 3% again, CMG901 receives a $45 million milestone payment from AstraZeneca.

KEYMED BIO-B (02162) rose by more than 3%, as of the press release, it rose by 2.21% to HK$55.5, with a turnover of HK$7.5096 million. In terms of news, Conova announced that according to the announcement, AstraZeneca announced that it has initiated a Phase III clinical trial (CLARITY-Gastric02) of AZD0901 in combination with Capetabine with or without rilvegostomig as first-line treatment for Claudin18.2-positive, HER2-negative advanced/metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma. The first subject has been dosed. Under the terms and conditions of the licensing agreement, the completion of the dosing of the first subject in the above clinical trial has triggered milestone payments, totaling $45 million. AstraZeneca has paid the milestone payment. Public information shows that KYM Biosciences Inc., a joint venture established by Conova and Lepu Biotechnology (in which Conova owns a 70% stake), entered into a global exclusive license agreement with AstraZeneca in 2023 for the development and commercialization of CMG901 globally.